OXCARBAZEPINE - Generic Drug Details

What are the generic drug sources for oxcarbazepine and what is the scope of freedom to operate?

Oxcarbazepine is the generic ingredient in three branded drugs marketed by Alkem Labs Ltd, Amneal Pharms, Aucta, Biocon Pharma, Bionpharma, Chartwell Rx, Hetero Labs Ltd Iii, Hikma, Kanchan Hlthcare, Macleods Pharms Ltd, Pai Holdings, Rubicon Research, Sun Pharm Inds Ltd, Novartis, Ajanta Pharma Ltd, Apotex, Aurobindo Pharma Ltd, Riconpharma Llc, Supernus Pharms, Ani Pharms, Annora Pharma, Breckenridge Pharm, Glenmark Pharms Ltd, Jubilant Cadista, Sun Pharm Inds, Taro, and Zydus, and is included in thirty-one NDAs. There are eleven patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Oxcarbazepine has fourteen patent family members in ten countries.

There are twenty-one drug master file entries for oxcarbazepine. Forty-one suppliers are listed for this compound. There are five tentative approvals for this compound.

Summary for OXCARBAZEPINE

International Patents:	14
US Patents:	11
Tradenames:	3
Applicants:	27
NDAs:	31
Drug Master File Entries:	21
Finished Product Suppliers / Packagers:	41
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	66
Patent Applications:	7,483
Drug Prices:	Drug price trends for OXCARBAZEPINE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OXCARBAZEPINE
What excipients (inactive ingredients) are in OXCARBAZEPINE?	OXCARBAZEPINE excipients list
DailyMed Link:	OXCARBAZEPINE at DailyMed

See drug prices for OXCARBAZEPINE

See drug sales revenues for OXCARBAZEPINE

Recent Clinical Trials for OXCARBAZEPINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Abbasi Shaheed Hospital	NA
Jinnah Postgraduate Medical Centre	PHASE4
Dr Cipto Mangunkusumo General Hospital	Phase 4

See all OXCARBAZEPINE clinical trials

Generic filers with tentative approvals for OXCARBAZEPINE

Applicant	Application No.	Strength	Dosage Form
		600MG	TABLET, EXTENDED RELEASE;ORAL
		300MG	TABLET, EXTENDED RELEASE;ORAL
		150MG	TABLET, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for OXCARBAZEPINE

Drug Class	Anti-epileptic Agent
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Anatomical Therapeutic Chemical (ATC) Classes for OXCARBAZEPINE

N03AF	Carboxamide derivatives
N03A	ANTIEPILEPTICS
N03	ANTIEPILEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for OXCARBAZEPINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OXTELLAR XR	Extended-release Tablets	oxcarbazepine	150 mg and 300 mg	202810	1	2013-04-12
OXTELLAR XR	Extended-release Tablets	oxcarbazepine	600 mg	202810	1	2013-03-20
TRILEPTAL	Oral Suspension	oxcarbazepine	300 mg/5 mL	021285	1	2006-12-26
TRILEPTAL	Tablets	oxcarbazepine	150 mg, 300 mg and 600 mg	021014	1	2006-05-05

US Patents and Regulatory Information for OXCARBAZEPINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-002	Oct 19, 2012	AB	RX	Yes	No			Y
Aurobindo Pharma Ltd	OXCARBAZEPINE	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	219241-001	Apr 30, 2025		DISCN	No	No
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-003	Oct 19, 2012	AB	RX	Yes	Yes			Y
Supernus Pharms	OXTELLAR XR	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	202810-002	Oct 19, 2012	AB	RX	Yes	No			Y
Novartis	TRILEPTAL	oxcarbazepine	TABLET;ORAL	021014-001	Jan 14, 2000	AB	RX	Yes	No
Ajanta Pharma Ltd	OXCARBAZEPINE	oxcarbazepine	TABLET, EXTENDED RELEASE;ORAL	217659-003	Feb 22, 2024	AB	RX	No	No

Expired US Patents for OXCARBAZEPINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TRILEPTAL	oxcarbazepine	SUSPENSION;ORAL	021285-001	May 25, 2001
Novartis	TRILEPTAL	oxcarbazepine	SUSPENSION;ORAL	021285-001	May 25, 2001
Novartis	TRILEPTAL	oxcarbazepine	TABLET;ORAL	021014-003	Jan 14, 2000
Novartis	TRILEPTAL	oxcarbazepine	TABLET;ORAL	021014-002	Jan 14, 2000
Novartis	TRILEPTAL	oxcarbazepine	TABLET;ORAL	021014-001	Jan 14, 2000

International Patents for OXCARBAZEPINE

Country	Patent Number	Title	Estimated Expiration
Japan	5253381
Germany	602007012236
Austria	E496623
Spain	2360423
European Patent Office	2026815	PRÉPARATIONS À LIBÉRATION CONTRÔLÉE D'OXCARBAZÉPINE AYANT UN PROFIL DE LIBÉRATION SIGMOÏDE (CONTROLLED RELEASED PREPARATIONS OF OXCARBAZEPINE HAVING SIGMOIDAL RELEASE PROFILE)
Japan	2009535351

OXCARBAZEPINE Market Analysis and Financial Projection

Last updated: February 12, 2026

Market Overview and Financial Trajectory for Oxcarbazepine

Oxcarbazepine, marketed primarily as Trileptal, is an anticonvulsant used in epilepsy treatment. Its market dynamics are driven by epilepsy prevalence, competitor landscape, generic entry, and regulatory environment. Financials are influenced by sales volume, pricing strategies, patent status, and licensing agreements.

---

How Does the Market Size and Growth of Oxcarbazepine Evolve?

The global anticonvulsant market, valued at approximately $4.1 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 5% through 2030, driven by increasing epilepsy prevalence, especially in aging populations and developing nations.

Oxcarbazepine accounts for an estimated 12-15% share within the anticonvulsants market, translating to around $490 million to $615 million in global sales in 2022. The drug's sales are expected to grow at a CAGR of about 4-6%, reflecting increased adoption for epilepsy management and off-label uses.

Key Drivers:

• Rising epilepsy cases, estimated at 50 million globally.
• Expanded approved indications, including trigeminal neuralgia.
• Competitive advantages over carbamazepine, such as fewer side effects and improved tolerability.

Constraints:

• Patent expiry in major markets, leading to price erosion.
• Market saturation with generic versions.
• Competition from newer antiepileptic drugs (AEDs) like levetiracetam and lacosamide.

---

What Are the Major Competitors and Market Share Dynamics?

Oxcarbazepine faces competition primarily from:

• Generic carbamazepine: Cost-effective, established alternative.
• Newer AEDs: Levetiracetam, lacosamide, and topiramate, offering different efficacy profiles.
• Other branded drugs: Eslicarbazepine (Aptiom), sharing structural similarity.

Market share shifts align with patent expirations:

Year	Patent Status	Effect on Sales	Major Competitors Entering Market
2000	Active patent	Growing sales	N/A
2010	Patent expiry in US	Decline of originator sales	Entry of generics
2014	Approaching loss of exclusivity in Europe	Price erosion accelerates	Market consolidation

Post-patent dynamics saw generic sales surpass branded sales, with generics capturing up to 90% of the market in certain regions by 2020.

---

What Is the Impact of Patent Status and Regulatory Changes?

• Patent Expiry: The US patent for Trileptal expired in October 2014; European patent expired in 2013. This resulted in widespread generic entry.
• Regulatory Approvals: Approval of oxcarbazepine in emerging markets and expansion for related indications enhances market reach.
• Pricing and Reimbursement: Many governments and insurers favor generics, pressuring brand-name drug prices downward.

The original producer, Novartis (now part of Swiss pharma companies), loses market exclusivity revenue post-patent. Companies often shift focus toward formulations with new delivery mechanisms or combination drugs.

---

How Do Pricing and Revenue Trends Evolve?

• Pre-patent expiry: Branded sales in developed markets averaged $600-700 per month per patient.
• Post-generics: Prices drop by 60-80%, leading to significant revenue decline for originators.
• Average Price Decline: In 2022, generic oxcarbazepine costs ranged from $0.50 to $1 per tablet, compared to $5-10 pre-patent expiry.

Revenue projections post-expiry decline sharply; for example, US sales for branded oxcarbazepine fell from $150 million in 2013 to less than $20 million in subsequent years.

---

What Are Future Revenue Outlooks?

Market forecasts assume the following:

• Continued generic penetration in mature markets, stabilizing at lower revenue levels.
• Expansion into emerging markets, where affordability drives uptake, with sales expected to grow from $150 million in 2022 to approximately $250 million in 2030.
• Patent extension strategies: Regulatory exclusivities and formulations with patent protection, such as controlled-release versions, potentially extending revenue streams until 2030 or later.

Potential future revenue sources include:

• Licensing deals for branded formulations.
• Combination drugs for epilepsy and neuralgia.
• Biosimilar development focusing on structural analogs.

---

What Are the Key Takeaways?

• Oxcarbazepine's global sales peaked pre-2014; subsequent patent expiry led to significant generic competition.
• The drug remains relevant, especially in markets with limited access to newer AEDs.
• Revenue prospects depend heavily on patent strategy, regional market growth, and competition from newer therapies.
• Generic erosion halved or more the originator's share in developed markets, but growth continues in developing regions.
• Future outlook relies on product innovation and licensing opportunities to offset declining legacy sales.

---

FAQs

1. When did the primary patents for oxcarbazepine expire?
The US patent expired in October 2014, and European patents expired around 2013.

2. How does generic competition affect revenue?
Generic competition typically reduces sales revenue for branded versions by 60-80%, leading to a sharp decline post-patent expiry.

3. What markets show the highest growth potential for oxcarbazepine?
Emerging markets, including India, China, and parts of Latin America, show increasing uptake driven by affordability and expanding healthcare coverage.

4. Are there new formulations of oxcarbazepine under development?
There are ongoing efforts to develop extended-release versions and combination therapies, which may extend patent protection and revenue.

5. What other drugs compete directly with oxcarbazepine?
Levetiracetam, lamotrigine, and lacosamide are primary competitors, often used as first-line or add-on treatments for epilepsy.

---

References

1. MarketWatch. "Anticonvulsant Market Size & Trends," 2022.
2. IQVIA. "Global Epilepsy Drugs Market Report," 2022.
3. Novartis Annual Report, 2013, 2014.
4. U.S. FDA Database. "Drug Approvals and Patent Status," 2022.
5. IMS Health. "Pharmaceutical Price and Sales Data," 2022.